State-of-the-art acute and chronic GVHD treatment

Muhammad Omer Jamil, Shin Mineishi

Research output: Contribution to journalReview articlepeer-review

67 Scopus citations


Graft-versus-host disease (GVHD) remains as the major obstacle for successful hematopoietic stem cell transplant (HSCT). Roughly half of the patients undergoing HSCT develop GVHD which requires treatment, and above 10 % of the patient may die because of it. However, GVHD presents with anti-tumor activity, called graft-versus-tumor (GVT) effect, and it carries significant anti-tumor activity, thus suppressing GVHD completely may increase the relapse of original disease. Thus, it is important to control GVHD to the appropriate level.

Original languageEnglish (US)
Pages (from-to)452-466
Number of pages15
JournalInternational journal of hematology
Issue number5
StatePublished - May 1 2015

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'State-of-the-art acute and chronic GVHD treatment'. Together they form a unique fingerprint.

Cite this